{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T20:01:22Z","timestamp":1696968082804},"reference-count":0,"publisher":"American Society for Microbiology","issue":"3","license":[{"start":{"date-parts":[[1995,5,1]],"date-time":"1995-05-01T00:00:00Z","timestamp":799286400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Clin Diagn Lab Immunol"],"published-print":{"date-parts":[[1995,5]]},"abstract":"<jats:p>An increase in B:15:P1.12 meningococci among isolates from patients with Neisseria meningitidis infection in Norway in recent years led to further characterization of such strains. Between 1987 and 1992, B:15:P1.12 strains constituted 9.8% (24 strains) of B:15 isolates. The B:15:P1.12 strains belonged to the electrophoretic type 5 (ET-5) complex, but 17 (71%) strains were a new clone (ET-5c) not found elsewhere in the world. All but one strain of ET-5c were responsible for a localized outbreak of systemic meningococcal disease in western Norway. A novel monoclonal antibody (202,G-12), developed against the unknown variable region 2 on the class 1 protein of one of these strains, bound to 19 of the 15:P1.12 strains, 4 strains bound the subtype P1.13 reference monoclonal antibody MN24H10.75, and the remaining strain showed no reaction. Sequencing of porA genes demonstrated a series of nine threonine residues in the deduced variable region 2 of the latter strain, while four and five threonine residues were found in the corresponding regions of strains reacting with the monoclonal antibodies 202,G-12 and MN24H10.75, respectively. Epitope mapping with synthetic peptides showed that 202,G-12 bound to a sequence of 11 amino acids which included the four threonine residues specific for subtype P1.13a. Immunoglobulin G antibodies against the P1.7,16 subtype protein, induced in volunteers after vaccination with the Norwegian meningococcal vaccine, did not cross-react on immunoblots with the subtype protein of clone ET-5c. Thus, postvaccination class 1 protein antibodies, assumed to be protective, may not be effective against infection with the new clone.<\/jats:p>","DOI":"10.1128\/cdli.2.3.314-321.1995","type":"journal-article","created":{"date-parts":[[2020,1,6]],"date-time":"2020-01-06T18:43:13Z","timestamp":1578336193000},"page":"314-321","update-policy":"http:\/\/dx.doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":19,"title":["Emergence of a new virulent clone within the electrophoretic type 5 complex of serogroup B meningococci in Norway"],"prefix":"10.1128","volume":"2","author":[{"given":"E","family":"Wedege","sequence":"first","affiliation":[{"name":"Department of Vaccine, National Institute of Public Health, Oslo, Norway."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Kolberg","sequence":"additional","affiliation":[{"name":"Department of Vaccine, National Institute of Public Health, Oslo, Norway."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Delvig","sequence":"additional","affiliation":[{"name":"Department of Vaccine, National Institute of Public Health, Oslo, Norway."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E A","family":"H\u00f8iby","sequence":"additional","affiliation":[{"name":"Department of Vaccine, National Institute of Public Health, Oslo, Norway."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Holten","sequence":"additional","affiliation":[{"name":"Department of Vaccine, National Institute of Public Health, Oslo, Norway."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Rosenqvist","sequence":"additional","affiliation":[{"name":"Department of Vaccine, National Institute of Public Health, Oslo, Norway."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D A","family":"Caugant","sequence":"additional","affiliation":[{"name":"Department of Vaccine, National Institute of Public Health, Oslo, Norway."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","container-title":["Clinical Diagnostic Laboratory Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/cdli.2.3.314-321.1995","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/cdli.2.3.314-321.1995","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,23]],"date-time":"2022-02-23T06:07:27Z","timestamp":1645596447000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/cdli.2.3.314-321.1995"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1995,5]]},"references-count":0,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1995,5]]}},"alternative-id":["10.1128\/cdli.2.3.314-321.1995"],"URL":"https:\/\/doi.org\/10.1128\/cdli.2.3.314-321.1995","relation":{},"ISSN":["1071-412X","1098-6588"],"issn-type":[{"value":"1071-412X","type":"print"},{"value":"1098-6588","type":"electronic"}],"subject":[],"published":{"date-parts":[[1995,5]]},"assertion":[{"value":"1995-05-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}